Interestingly osteonecrotic lesions in the jaw have also been reported within treatment regimes including Denosumab in cancer patients assuming that a blockade of receptor activator of nuclear factor-kappa-B (RANK) and receptor activator of nuclear factor-kappa-B- ligand (RANKL) interaction affects monocytic migration as well as osteoclast function comparable to Bisphosphonates [27]. Here, TNFRSF11A is linked to cancer.